S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
CVE:IPA

ImmunoPrecise Antibodies Stock Forecast, Price & News

C$7.72
-0.12 (-1.53 %)
(As of 10/22/2021 03:59 PM ET)
Add
Compare
Today's Range
C$7.55
C$7.84
50-Day Range
C$7.29
C$9.87
52-Week Range
C$6.39
C$26.25
Volume17,148 shs
Average Volume64,990 shs
Market CapitalizationC$149.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IPA News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.


About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
C$18.74 million
Cash Flow
C$2.10 per share
Book Value
C$2.88 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
C$149.36 million
Next Earnings Date
12/20/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.05 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












ImmunoPrecise Antibodies (CVE:IPA) Frequently Asked Questions

What stocks does MarketBeat like better than ImmunoPrecise Antibodies?

Wall Street analysts have given ImmunoPrecise Antibodies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImmunoPrecise Antibodies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ImmunoPrecise Antibodies' next earnings date?

ImmunoPrecise Antibodies is scheduled to release its next quarterly earnings announcement on Monday, December 20th 2021.
View our earnings forecast for ImmunoPrecise Antibodies
.

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (CVE:IPA) announced its quarterly earnings data on Wednesday, July, 28th. The company reported ($0.29) earnings per share (EPS) for the quarter. The company earned $4.88 million during the quarter.
View ImmunoPrecise Antibodies' earnings history
.

How has ImmunoPrecise Antibodies' stock price been impacted by Coronavirus (COVID-19)?

ImmunoPrecise Antibodies' stock was trading at C$0.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IPA stock has increased by 957.5% and is now trading at C$7.72.
View which stocks have been most impacted by COVID-19
.

Who are ImmunoPrecise Antibodies' key executives?

ImmunoPrecise Antibodies' management team includes the following people:
  • Dr. James S. Kuo M.B.A., M.D., Independent Chairman (Age 56)
  • Dr. Jennifer Lynne Bath Ph.D., CEO, Pres & Director
  • Ms. Lisa Helbling, Chief Financial Officer
  • Dr. Yasmina Noubia Abdiche Ph.D., Chief Scientific Officer
  • Dr. Stefan Lang, Chief Bus. Officer
  • Mr. David E. Orton, Chief Operating Officer
  • Ms. Lauren Smith, VP of Marketing and Sales

What other stocks do shareholders of ImmunoPrecise Antibodies own?

What is ImmunoPrecise Antibodies' stock symbol?

ImmunoPrecise Antibodies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IPA."

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is ImmunoPrecise Antibodies' stock price today?

One share of IPA stock can currently be purchased for approximately C$7.72.

How much money does ImmunoPrecise Antibodies make?

ImmunoPrecise Antibodies has a market capitalization of C$149.36 million and generates C$18.74 million in revenue each year.

How many employees does ImmunoPrecise Antibodies have?

ImmunoPrecise Antibodies employs 2,021 workers across the globe.

What is ImmunoPrecise Antibodies' official website?

The official website for ImmunoPrecise Antibodies is immunoprecise.com.

Where are ImmunoPrecise Antibodies' headquarters?

ImmunoPrecise Antibodies is headquartered at 880-580 Hornby St, VANCOUVER, BC V6C 3B6, Canada.

How can I contact ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies' mailing address is 880-580 Hornby St, VANCOUVER, BC V6C 3B6, Canada. The company can be reached via phone at +1-604-8060626.


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.